Сравнение

Icatibant vs. Selank

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

138614-30-9

129954-34-3

Молекулярная масса

1304.52 g/mol

751.85 g/mol

Период полувыведения

нет данных

0.3 h

Последовательность

нет данных

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Механизм действия

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Selank

Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследование на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Icatibant	Selank
Германия	Рецептурный	Не одобрено
RU	—	Рецептурный
США	Рецептурный	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Icatibant and Selank?: Icatibant is classified as "Исследования (прочее)", while Selank is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Selank?: The highest available evidence level is "РКИ на людях" for Icatibant and "Исследование на людях" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Selank in Germany and the United States?: Германия: Icatibant — Рецептурный, Selank — Не одобрено. США: Icatibant — Рецептурный, Selank — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Selank

Германия

Рецептурный

Не одобрено

—

Рецептурный

США

Рецептурный

Не одобрено

Frequently asked questions

What is the difference between Icatibant and Selank?

Icatibant is classified as "Исследования (прочее)", while Selank is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Selank?

The highest available evidence level is "РКИ на людях" for Icatibant and "Исследование на людях" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Selank in Germany and the United States?

Германия: Icatibant — Рецептурный, Selank — Не одобрено. США: Icatibant — Рецептурный, Selank — Не одобрено. These are factual summaries with source and review date on the individual pages.